RESUMEN
Several long non-coding RNA (lncRNA) might be correlated with the prognosis of colorectal cancer (CRC) and serve as a diagnostic and prognostic biomarker. However, the exact expression pattern of small nucleolar RNA host gene 12 (SNHG12) in colorectal cancer and its clinical significance remains unclear. The level of SNHG12 was detected by qRT-PCR in CRC tissues and CRC cells. MTT assay and colony formation assay were performed to examine the cell proliferation of CRC cells transfected with pcDNA-SNHG12 or si-SNHG12. Flow cytometry technology was used to detect cell cycle and cell apoptosis of CRC cells transfected with pcDNA-SNHG12 or si-SNHG12. The protein level of cell cycle progression-related molecules, including cyclin-dependent kinases (CDK4, CDK6), cyclin D1 (CCND1) and cell apoptosis-related molecule caspase 3 was detected by western blot. The effect of SNHG12 knockdown was examined in vivo. Increased levels of SNHG12 were observed in CRC tissues and in CRC cells. SNHG12 promoted the cell proliferation of CRC cells. In addition, SNHG12 overexpression boosted the cell cycle progression of SW480 cells transfected with pcDNA-SNHG12 and SNHG12 knockdown inhibited the cell cycle progression of HT29 cells transfected with si-SNHG12. SNHG12 also inhibited the cell apoptosis of CRC cells. We also found that SNHG12 increased the expression of cell cycle-related proteins and suppressed the expression of caspase 3. Our results suggest that SNHG12 promoted cell growth and inhibited cell apoptosis in CRC cells, indicating that SNHG12 might be a useful biomarker for colorectal cancer.
Asunto(s)
Apoptosis , Proliferación Celular/fisiología , Neoplasias Colorrectales/metabolismo , ARN Largo no Codificante/fisiología , Western Blotting , Citometría de Flujo , Regulación Neoplásica de la Expresión Génica , Humanos , Reacción en Cadena en Tiempo Real de la Polimerasa , Regulación hacia ArribaRESUMEN
The objective of this study was to evaluate the estrogenic effects and mechanisms of three flavonoid components in Xiaoyao powder: quercetin, kaempferol, and isorhamnetin. The drugs were used to treat estrogen receptor (ER)-positive human breast cancer MCF-7 cells, and proliferation was measured using the MTT method. The expression of proteins and mRNA of the ER subtype were measured using western blotting and real time polymerase chain reaction. The quercetin (10(-2) µM, 10(-3) µM), kaempferol (100 µM, 10(-2) µM), and isorhamnetin (10(-3) µM) promoted the proliferation of MCF-7 cells, and the expression of ERα and ERß proteins and mRNA were all increased significantly (P < 0.05). These effects were reversed by treatment with 0.1 µM estrogen antagonist ICI182780. Three flavonoid components in Xiaoyao powder increased the expression of proteins and mRNA of ERα and ERß and promoted the proliferation of MCF-7 cells. These estrogenic effects were mediated by the ER.
Asunto(s)
Medicamentos Herbarios Chinos/química , Receptor alfa de Estrógeno/genética , Receptor beta de Estrógeno/genética , Quempferoles/farmacología , Quercetina/análogos & derivados , Quercetina/farmacología , ARN Mensajero/genética , Antineoplásicos/farmacología , Proliferación Celular/efectos de los fármacos , Receptor alfa de Estrógeno/agonistas , Receptor alfa de Estrógeno/metabolismo , Receptor beta de Estrógeno/agonistas , Receptor beta de Estrógeno/metabolismo , Ácido Fólico/análogos & derivados , Ácido Fólico/farmacología , Regulación Neoplásica de la Expresión Génica , Humanos , Quempferoles/antagonistas & inhibidores , Células MCF-7 , Polvos/química , Quercetina/antagonistas & inhibidores , ARN Mensajero/agonistas , ARN Mensajero/metabolismo , Transducción de SeñalRESUMEN
This study aimed to analyze the association between the 405G/C and -2578C/A polymorphisms of the vascular endothelial growth factor (VEGF) gene and breast cancer risk by meta-analysis. A systematic computerized search of PubMed, Google Scholar, and Web of Science databases was performed to identify relevant publications. After rigorous searching and screening, 9 eligible case-control studies were included in this meta-analysis. The associations between the VEGF gene 405G/C and -2578C/A polymorphisms and breast cancer risk were estimated by pooled ORs and 95%CIs using fixed- or random-effect models. Meta-analysis results showed no significant association between the 405G/C polymorphism and breast cancer risk (CC vs GG: OR = 1.04, 95%CI = 0.92-1.17; CC vs GC: OR = 1.04, 95%CI = 0.93-1.17; dominant model: OR = 0.95, 95%CI = 0.85-1.06; recessive model: OR = 0.92, 95%CI = 0.70-1.20). The results also did not show significant association for the -2578C/A polymorphism: (AA vs CC: OR = 1.03, 95%CI = 0.91-1.15; AA vs GA: OR = 0.99, 95%CI = 0.89-1.10; dominant model: OR = 1.00, 95%CI = 0.90-1.10; recessive model: OR = 1.03, 95%CI = 0.94-1.13). Similar results were observed in the subgroup analyses on ethnicity, sample size, and Hardy-Weinberg equilibrium. These findings suggested a lack of association between the VEGF gene 405G/C and -2578C/A polymorphisms and breast cancer susceptibility.